Last edition
News about "Hypertrophic Cardiomyopathy"
FDA Clears IND Application for Chengdu Origen's Gene Therapy Targeting Hypertrophic Cardiomyopathy
Chengdu Origen Biotechnology and Vanotech have received US FDA clearance to begin clinical evaluation of KHN921, a potential first-in-class gene therapy designed to address the genetic root cause of hypertrophic cardiomyopathy linked to MYBPC3 mutations.
Hypertrophic Cardiomyopathy | 16/05/2026 | By News Bureau
China's NMPA Approves Sanofi-Licensed Myqorzo and Redemplo for Rare Cardiac and Lipid Disorders
Myqorzo and Redemplo approvals by NMPA expand treatment options for obstructive hypertrophic cardiomyopathy and familial chylomicronaemia syndrome in adult patients across Greater China.
Hypertrophic Cardiomyopathy | 17/01/2026 | By News Bureau | 286
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy